TITLE

Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure

PUB. DATE
May 2002
SOURCE
ACP Journal Club;May/Jun2002, Vol. 136 Issue 3, p83
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Deals with the study which examined the renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Outcome measures; Results; Conclusion.
ACCESSION #
8856084

 

Related Articles

  • ACE inhibitors dominant for newly diagnosed T2DM.  // PharmacoEconomics & Outcomes News;8/11/2007, Issue 534, p4 

    The article discusses research being done on the diagnosis of type 2 diabetes mellitus (T2DM). It references a study by H. M. Campbell, K. D. Boardman, M. A. Dodd and D. W. Raisch, published in the July-August 2007 issue of "Annals of Pharmacotherapy." According to the researchers, the...

  • Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). Imai, Enyu; Haneda, Masakazu; Chan, Juliana C.N.; Yamasaki, Tetsu; Kobayashi, Fumiaki; Ito, Sadayoshi; Makino, Hirofumi // Nephrology Dialysis Transplantation;Oct2013, Vol. 28 Issue 10, p2526 

    Background Proteinuria is a major predictor for progression of renal disease, including diabetic nephropathy. In a post hoc analysis of the ORIENT, a double-blinded randomized trial of 566 type 2 diabetic patients with nephropathy, we examined the risk association of composite renal outcome...

  • Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. Appel, Gerald B.; Radhakrishnan, Jai; Avram, Morrell M.; DeFronzo, Ralph A.; Escobar-Jimenez, Fernando; Campos, M. M.; Burgess, Ellen; Hille, Darcy A.; Dickson, Tania Z.; Shahinfar, Shahnaz; Brenner, Barry M. // Diabetes Care;May2003, Vol. 26 Issue 5, p1402 

    OBJECTIVE — Metabolic factors such as glycemic control, hyperlipidemia, and hyperkalemia are important considerations in the treatment of patients with type 2 diabetes and nephropathy. In the RENAAL (Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan)...

  • Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Andersen, Steen; Bröchner-Mortensen, Jens; Parving, Hans-Henrik; Bröchner-Mortensen, Jens; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3296 

    OBJECTIVE — Irbesartan is renoprotective in patients with type 2 diabetes and microalbuminuria. Whether the observed reduction in microalbuminuria is reversible (hemodynamic) or persistent (glomerular structural/biochemical normalization) after prolonged antihypertensive treatment is...

  • Use CCBs with Caution in Blacks with Diabetic Nephropathy.  // Kidney;Jan/Feb98, Vol. 7 Issue 1, p18 

    Investigates the contrasting effects of calcium channel blockade versus angiotensin converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. Effects of isradapine on the course of nephropathy as compared with those of...

  • ACE inhibitors/losartan/metformin.  // Reactions Weekly;1/27/2007, Issue 1136, p4 

    The article discusses several case studies involving the development of lactic acidosis and renal failure during treatment with metformin. It references a study by H. Aksnes et al published in the November 2006 issue of the journal "Clinical Nephrology." The patients were treated with metformin...

  • Metformin: expanded use for patients with kidney impairment.  // Reactions Weekly;10/29/2016, Vol. 1625 Issue 1, p5 

    The article reports on the expansion of the use of medicines containing metformin for the treatment of type 2 diabetes mellitus (T2DM) in patients with moderately reduced kidney function according to the pharmaceutical authority European Medicines Agency.

  • First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation. Zidek, Walter; Schrader, Joachim; L�ders, Stephan; Matthaei, Stephan; Hasslacher, Christoph; Hoyer, Joachim; Bramlage, Peter; Sturm, Claus-Dieter; Paar, W. Dieter // Cardiovascular Diabetology;2008, Vol. 7, p1 

    Background: Recent clinical trials reported conflicting results on the reduction of new-onset diabetes using RAS blocking agents. Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular...

  • Aqueous Extracts from Unripe Plantain (Musa paradisiaca) Products Inhibit Key Enzymes Linked with Type 2 Diabetes and Hypertension in vitro. Adamson, Shodehinde S.; Ganiyu, Oboh // Jordan Journal of Biological Sciences;Dec2012, Vol. 5 Issue 4, p239 

    Mature green plantains bought at Oja-Oba in Akure were roasted into a local meal called 'boli' while another portion was boiled in water. Each of the samples was sun dried and milled into flour. The aqueous extracts of roasted and boiled were prepared (10g/100mL). The study was based on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics